Nicholas Company Inc. Purchases 303 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Nicholas Company Inc. raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.4% in the 4th quarter, Holdings Channel reports. The firm owned 84,404 shares of the medical research company’s stock after buying an additional 303 shares during the period. Nicholas Company Inc.’s holdings in IQVIA were worth $16,586,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Synergy Asset Management LLC bought a new stake in IQVIA in the fourth quarter valued at approximately $33,000. Avior Wealth Management LLC increased its stake in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares in the last quarter. Assetmark Inc. increased its position in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares in the last quarter. Meeder Asset Management Inc. increased its position in shares of IQVIA by 353.7% during the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock worth $58,000 after acquiring an additional 191 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $185.40 on Friday. The firm has a 50-day moving average of $196.63 and a 200-day moving average of $210.69. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market cap of $32.69 billion, a PE ratio of 24.72, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $256.34.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IQV. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Barclays lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. UBS Group decreased their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.